Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
BUSINESS Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
-
BUSINESS Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
-
BUSINESS Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
-
REGULATORY 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
-
BUSINESS Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
-
BUSINESS Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
-
BUSINESS Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
-
BUSINESS MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
-
REGULATORY Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
-
REGULATORY Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use
April 15, 2024
-
BUSINESS Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
-
BUSINESS Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
-
BUSINESS Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
-
REGULATORY Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
-
BUSINESS Moderna, Tohoku Biobank Start Epidemiology Study on Latent Viruses
April 12, 2024
-
BUSINESS ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
-
BUSINESS Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
-
REGULATORY Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
-
REGULATORY Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
-
REGULATORY Average PMP Rate Hits Record Low at 1.2% in FY2024: MHLW
April 11, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…